Abstract
Despite the use of aggressive trimodality therapy consisting of neoadjuvant chemotherapy, surgery, and hemithoracic radiation, the median survival of patients with malignant pleural mesothelioma (MPM) is 12 to 18 months (1,2). Immune responses have been shown to be beneficial in MPM patients (3,4); therefore, focusing immunotherapeutic strategies on promoting these immune responses is an attractive approach. One such approach involves targeting cancer-associated antigens highly expressed on mesothelioma cells by use of monoclonal antibodies, recombinant immunotoxins, vaccines, or genetically engineered T cells. Targeted antigens can be either cell-surface antigens, such as mesothelin, or intracellular antigens, such as WT-1. Cell-surface antigens are favored for the immunotherapeutic approach because of their ease of targeting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
